Analysis of Long-Term Prognostic Factors Based on Nutritional Status in Patients with Multiple Myeloma.
10.19746/j.cnki.issn.1009-2137.2023.02.021
- Author:
Ke-Wa MA
1
;
Jian-Nan YE
1
;
Jing-Jue MAO
1
;
Xin ZHOU
2
;
Chao SUN
3
;
Jian-Yong LI
4
Author Information
1. Department of Hematology, The Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi 214023, Jiangsu Province, China.
2. Department of Hematology, The Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi 214023, Jiangsu Province, China. E-mail: zx89232@126.com.
3. Department of Hematology, The Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi 214023, Jiangsu Province, China.E-mail:13057302309sun@163.com.
4. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
- Publication Type:Journal Article
- Keywords:
CONUT score;
multiple myeloma;
prognostic factors;
risk stratification
- MeSH:
Humans;
Nutritional Status;
Prognosis;
Multiple Myeloma;
Retrospective Studies;
Risk Factors
- From:
Journal of Experimental Hematology
2023;31(2):455-461
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the prognostic factors of patients with multiple myeloma (MM) based on nutritional status.
METHODS:The Controlling Nutritional Status (CONUT) score and clinical parameters at diagnosis of 203 newly diagnosed MM patients hospitalized in the department of hematology, Wuxi People's Hospital from January 1, 2007 to June 30, 2019 were analyzed retrospectively. The best cut-off value was determined by ROC curve, and the patients were divided into high CONUT group (>6.5 points) and low CONUT group (≤6.5 points); through COX regression multivariate analysis of overall survival (OS) time, CONUT, ISS stage, LDH and treatment response were selected for multiparameter prognostic stratification.
RESULTS:The OS of MM patients in high CONUT group was shorter. The low-risk group (≤2 points) of the multiparameter risk stratification had longer OS time and progression-free survival (PFS) time compared with the high-risk group (>2 points), and it was also effective for different age or karyotype subgroups, new drug groups containing bortezomib and transplant-ineligible subgroup.
CONCLUSION:The risk stratification of MM patients based on CONUT, ISS stage, LDH and treatment response is worthy of clinical application.
